ArticleFrontiers in oncology2026
Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: RAC1, a Rho GTPase family member involved in cell motility, is irregularly expressed in solid tumors. However, the specific tumor cell states in which RAC1 operates and its influence on the immune microenvironment remain poorly understood. Methods: RAC1 expression and prognostic value were evaluated across cancers using TCGA, HPA, CPTAC, and GEO data. After identifying GBM as the most prognostically relevant cancer type, Lasso-Cox regression and multivariate Cox analysis confirmed RAC1 as the key prognostic member among Rho GTPase family members. RAC1 expression was validated in GBM cell lines and mouse tumor tissues by qPCR and Western blotting. Effects on proliferation, migration, and invasion were assessed by CCK-8, wound healing, and Transwell assays. Immune infiltration, immunotherapy responsiveness, and drug sensitivity were analyzed using TCGA data. Single-cell RNA sequencing analysis was performed to resolve RAC1 expression across tumor cell states and the immune microenvironment. Molecular docking and Results: RAC1 was upregulated in most cancers, with the highest prognostic accuracy in GBM. Lasso-Cox regression retained RAC1 across OS, DSS, and PFI endpoints, and multivariate Cox analysis confirmed it as the sole family member with HR exceeding 2 (HR = 2.61, P = 0.003). NSC23766 suppressed GBM cell proliferation, migration, and invasion without altering total RAC1 protein, confirming dependence on RAC1 activation state. Single-cell analysis revealed RAC1 enrichment in the NPC-like tumor state, independent of cell cycle. RAC1-high cells exhibited PI3K-AKT-mTOR and IFN-gamma pathway activation with upregulated MHC-I but absent PD-L1, explaining ICI resistance. Palbociclib inhibited GBM cell viability in a dose- and time-dependent manner. Conclusion: RAC1 serves as a prognostic biomarker and therapeutic stratification indicator in GBM, marking IFN-responsive tumor subpopulations that may benefit from CDK4/6 inhibitor-based strategies rather than ICI monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.